Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR), Edmonton, Alberta, Canada.
Clin Pharmacol Ther. 2017 Oct;102(4):588-590. doi: 10.1002/cpt.747. Epub 2017 Jul 10.
The development of new therapies for inflammatory bowel disease is plagued by high costs, potential side effects, and variable levels of effectiveness. Fecal microbial transplant in inflammatory bowel diseases can offer an alternative to traditionally developed pharmacologic therapies and has demonstrated the ability to induce disease remission in randomized control trials. However, questions remain about the ultimate role of this therapy in disease management, including long term safety, and the optimal composition of transplanted stool.
炎症性肠病新疗法的开发受到高成本、潜在副作用和疗效差异的困扰。在炎症性肠病中,粪便微生物移植可以替代传统开发的药物治疗,并已在随机对照试验中证明能够诱导疾病缓解。然而,关于这种治疗在疾病管理中的最终作用,包括长期安全性和移植粪便的最佳组成,仍存在一些问题。